PH12014501044A1 - Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells - Google Patents
Methods for improved wound closure employing olivamine and human umbilical vien endothelial cellsInfo
- Publication number
- PH12014501044A1 PH12014501044A1 PH12014501044A PH12014501044A PH12014501044A1 PH 12014501044 A1 PH12014501044 A1 PH 12014501044A1 PH 12014501044 A PH12014501044 A PH 12014501044A PH 12014501044 A PH12014501044 A PH 12014501044A PH 12014501044 A1 PH12014501044 A1 PH 12014501044A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- olivamine
- vien
- endothelial cells
- compositions
- Prior art date
Links
- 210000002889 endothelial cell Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 abstract 2
- 230000017074 necrotic cell death Effects 0.000 abstract 2
- 230000029663 wound healing Effects 0.000 abstract 2
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 abstract 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 abstract 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 210000004700 fetal blood Anatomy 0.000 abstract 1
- 235000003248 hydroxytyrosol Nutrition 0.000 abstract 1
- 229940095066 hydroxytyrosol Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 235000011576 oleuropein Nutrition 0.000 abstract 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/832,188 US8796315B2 (en) | 2009-06-25 | 2013-03-15 | Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells |
PCT/US2014/022490 WO2014150174A1 (en) | 2013-03-15 | 2014-03-10 | Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells |
Publications (2)
Publication Number | Publication Date |
---|---|
PH12014501044A1 true PH12014501044A1 (en) | 2015-01-12 |
PH12014501044B1 PH12014501044B1 (en) | 2015-01-12 |
Family
ID=51580709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12014501044A PH12014501044B1 (en) | 2013-03-15 | 2014-05-08 | Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells |
Country Status (2)
Country | Link |
---|---|
PH (1) | PH12014501044B1 (en) |
WO (1) | WO2014150174A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160354411A1 (en) * | 2015-06-05 | 2016-12-08 | Darlene E. McCord | Olivamine-induced improvement in endothelial cells viability and function |
AU2017217527A1 (en) * | 2016-02-08 | 2018-08-23 | Hackensack University Medical Center | Compositions and methods for treating chronic wounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2000258901A1 (en) * | 2000-04-06 | 2001-10-23 | Nicholas V. Perricone | Treatment of skin damage using olive oil polyphenols |
WO2003068171A2 (en) * | 2002-02-13 | 2003-08-21 | Creagri, Inc. | Method and composition for treatment of inflammation and aids-associated neurological disorders |
US20070207228A1 (en) * | 2004-03-02 | 2007-09-06 | Giammaria Giuliani | Composition for Regulating the Trophism of Hair Follicles and the Cutaneous Production of Sebum and Use Thereof in Androgenic Alopecia |
CN101516364B (en) * | 2006-07-14 | 2011-12-28 | 帝斯曼知识产权资产管理有限公司 | Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders |
WO2010151778A2 (en) * | 2009-06-25 | 2010-12-29 | Darlene Mccord | Topical compositions and methods for wound care |
-
2014
- 2014-03-10 WO PCT/US2014/022490 patent/WO2014150174A1/en active Application Filing
- 2014-05-08 PH PH12014501044A patent/PH12014501044B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014150174A1 (en) | 2014-09-25 |
PH12014501044B1 (en) | 2015-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
MX2021014709A (en) | Methods for increasing red blood cell levels and treating sickle-cell disease. | |
MX2021010528A (en) | Methods and compositions for treating ulcers. | |
EA201301354A1 (en) | SGLT-2 INHIBITORS DESIGNED FOR THE TREATMENT OF METABOLIC DISORDERS IN PATIENTS TREATED BY NEUROLEPTICS | |
BR112017000301A2 (en) | treatment of leukemia with histone deacetylase inhibitors | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
MX2019008085A (en) | Activin-actrii antagonists and uses for treating bone and other disorders. | |
CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
EA201500996A1 (en) | THERAPEUTIC APPLICATIONS OF EMAGOGLIFLOSINE | |
EA201591674A1 (en) | ANTI-TRACT VACCINES AND TREATMENT METHODS WITH THEIR APPLICATION | |
MX2016007351A (en) | Combination therapy for treating cancer. | |
MX363243B (en) | Compositions and methods for treating cancer. | |
MX2016004678A (en) | Methods and compositions for treating cancer. | |
EA201291031A1 (en) | METHOD OF TREATING OBESITY WITH THE USE OF ANTIOXIDANT INFLAMMATION MODULATORS | |
MX2015016100A (en) | Cryopyrin inhibitors for preventing and treating inflammation. | |
BR112015029386A2 (en) | use of eribulin and lenvatinib as combination therapy for cancer treatment | |
EA201590703A1 (en) | MEK INHIBITORS FOR TREATING VIRAL DISEASES | |
MX2017006015A (en) | Apilimod for use in the treatment of renal cancer. | |
MX2015014599A (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer. | |
EA201591543A1 (en) | COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS | |
WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
EA201591424A1 (en) | METHODS OF TREATMENT OF IRON DEFICIENCY WITH SOLUBLE IRON PYROPHOSPHATE | |
EA032501B9 (en) | Methods and compositions for promoting acute wound and chronic wound healing | |
MX2015012444A (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens. | |
MX2017006026A (en) | Apilimod for use in the treatment of colorectal cancer. |